Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS
Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS
Recruiting · NCT05834855 · Registry updated 2023-04-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS | CNS demyelinating autoimmune disease, Leukoencephalopathies, autoimmune disease, autoimmune disorder of the nervous system, brain disorder, central nervous system disorder, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder, relapsing-remitting multiple sclerosis | Recruiting | Phase 3 | 2023-04-28 | NCT05834855 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Amsterdam UMC, location VUmc | 102 |
| Stichting Treatmeds | 4 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Amsterdam UMC, location VUmc | Amsterdam | Netherlands | 4 |